1. “Perm state medical University named after academician E. A. Wagner” of Ministry of health of Russia (Perm, Russian Federation)

Keywords:cholelithiasis,biliary sludge,postcholecystectomy syndrome,classification,treatment

Abstract:In the overview article discusses: the prevalence of cholelithiasis, the frequency of the related surgical interventions, controversial problems with terminology, the concept of “biliary sludge”. Brief information about the elements of cholelithiasis; etiology and pathogenesis of postcholecystectomy syndrome - PHES and its definition; different approaches to the definition of its nature, the working classification of PHES. Specify modern methods of diagnosis PHES. Discusses in detail the contemporary possibilities of pharmacotherapy and their effectiveness, indications for surgical treatment and basic preventive measures.

• References total 54 ⇓ :: .
  1. Максимов В. А., Цицеров В. И., Чернышев А. Л., Тарасов К. М. Распространённость холелитиаза по данным вскрытий / Практикующий врач, 1997; 10 (3): 12-13.
  2. Виноградов В. В. Послеоперационные заболевания желчных путей / В кн.: Постхолецистэктомические синдромы и сопутствующие заболевания - Пленум правления ВНОГ / под ред. В. Х. Василенко. - М. - Рязань, 1980.
  3. Kratzer W., Kachele V., Mason R. A. et al. Gallstone frequency in Germany/ Dig. Dis. Sci., 1998; 43: 1285-1291.
  4. Василенко В. Х. (ред.) Постхолецистэктомические синдромы и сопутствующие заболевания / Пленум правления ВНОГ. - М. - Рязань, 1980.
  5. Дидвани С. А., Ветшев П. С., Шулутко А. Т., Прудков М. И. Желчнокаменная болезнь. - М., 2000.
  6. Ильченко А. А. Желчнокаменная болезнь. - М., 2005.
  7. Иванченкова Р. А. Постхолецистэктомический синдром / В кн.: Руководство по гастроэнтерологии в 3 т. / Под ред. Ф. И. Комарова и А. Л. Гребенева, - М., 1995; 3: 475-491.
  8. Моск Н. Е. Postcholecystectomy syndrome / M. Clin. North Amer., 1953; 37: 169-176.
  9. McHardy G. Postcholecystectomy syndrome / J. Kansas City Southwest Clin. Soc. (Dec.), 1959; 1: 1-18.
  10. Berk J. E. Postcholecystectomy syndrome / Amer. J. Dig. Dis., 1961;6: 1002-1011.
  11. Циммерман Я. С., Кунстман Т. Г. Постхолецистэктомический синдром: современный взгляд на проблему / Клин. мед., 2006; 8: 4-11.
  12. Иванченкова Р. А. Правомочен ли термин «постхолецистэктомический синдром»? / Российск. журн. гастроэнтерол., гепатол. и колопроктол., 1998; 5 (Прил.): 185-186.
  13. Малле-Ги П., Кестенс П. Синдром после холецистэктомии (перев. с франц.). - М., 1973.
  14. Циммерман Я.С, Циммерман И. Я. Классификации гастроэнтерологических заболеваний и клинических синдромов. 5-е изд., - Пермь, 2016.
  15. Мараховский Ю. Х. Желчнокаменная болезнь: на пути к диагностике ранних стадий патологического процесса в желчном пузыре / Российск. журн. гастроэнтерол., гепатол. и колопроктол., 1994; 4: 6-19.
  16. Циммерман Я. С. Болезнь Гиршспрунга у взрослых / Клин. мед., 2011; 4: 60-63.
  17. Шерлок Ш., Дули Дж. Заболевания печени и желчных путей / Перев. с англ. - М., 1999.
  18. Лейшнер У. Практическое руководство по заболеваниям желчных путей / Перев. с нем. - М., 2001.
  19. Циммерман Я. С. Современные представления о камнеобразовании в желчном пузыре и место билиарного сладжа в этом процессе / Клин. мед., 2010; 5: 13-19.
  20. Ильченко А. А., Делюкина О. В. Билиарный сладж, как начальная стадия желчнокаменной болезни / Экспер. и клин. гастроэнтерол., 2004; 1: 56-57.
  21. Чубенко С. Е. Микрохолелитиаз / Doctor, 2004; 3: 23-24.
  22. Губергриц Н. Б. Билиарный сладж: констатировать или лечить?/ Вестн. клуба панкреатол., 2009; 1(2): 91-99 (Украина).
  23. De la Porte P. L., Lafont H., Domingo N. et al. Composition and immunofluorescence studies of biliary “sludge” in patients with cholesterol or mixed gallstones / J. Hepatol., 2000; 33: 252-260.
  24. Ko C. W., Senijirna J. H., Lee S. P. Biliary sludge / Ann. Intern. Med., 1999; 130: 301-311.
  25. Боткин С. П. О желчной колике / В кн.: «Курс клиники внутренних болезней и клинические лекции». - М., 1950.
  26. Lee D. K., Tarr P. I., Haigh W. G., Lee S. P. Bacterial DNA in mixed cholesterol gallstones / Am. J. Gastroenterol., 1999; 94: 3502-3506.
  27. Kowai M., Berr F., Thomas L. A. et al. Gram-positive cocci are assotiated with the formation of completely pure cholesterol stones / Am. J. Gastroenterol., 2002; 97: 83-88.
  28. Wells J. E., Beer F., Thomas L. A. et al. Isolation and characterization of chronic acid-7α-dehydroxylaring fecal bacteria from cholesterol gallstone patients / J. Hepatology, 2000; 32: 4-10.
  29. Федоров С. П. Желчные камни и хирургия желчных путей. - М., 1934.
  30. Циммерман Я. С., Бондарь О. Д., Щекотова А. П. Биохимия и литогенные свойства желчи при билиарной патологии / Клин. мед., 1981; 4: 48-51.
  31. Скуя Н. А. Хронические заболевания желчных путей. - Ленинград, 1978.
  32. Виноградов В. В., Мазаев П. Н., Зима П. И. Диагностика холецистита. - М., 1978.
  33. Федорова Н. П. Случай врожденного отсутствия желчного пузыря / Клин. мед., 1997; 1: 44-45.
  34. Мараховский Ю. Х. Желчнокаменная болезнь: современное состояние проблемы/ Российск. журн. гастроэнтерол., гепатол. и колопроктол., 2003; 1: 81-92.
  35. Иванченкова Р. А. Некоторые аспекты желчеобразования / Клин. мед., 1999; 7: 18-22.
  36. Admirand W. H., Small D. M. The physiochemical basis of cholesterol gallstone formatiom in men / J. Clin. Invest., 1968; 47: 1043-1052.
  37. Corradini S. G., Elisei W., Giovanelli L. et al. Impraised human gallbladder lipid absorption in cholesterol solubility in bile / Gastroenterology, 2000; 118: 912-920.
  38. Drossman D. A. The functional gastrointestinal disorders and the Rome-II process/ Gut, 1999; 45 (Suppl. 1): 111-115.
  39. Ильченко А. А. Дисфункциональные расстройства билиарного тракта / Consilium medicum, 2002; 1 (Прил.): 20-23.
  40. Маев И. В., Самсонов., А.А., Сасова Л. М. Дисфункциональные расстройства билиарного тракта: пособие для врачей. - М., 2006.
  41. Циммерман Я. С. Синдром хронической дуоденальной непроходимости: современный взгляд на проблему / Клин. мед., 2009; 10: 9-16.
  42. Berger Z., Pimental C., Madrid A. M. et. al. Endoscopic manometry of Oddi`s sphincter / Rev. Med. Clin., 1997; 125 (11): 1343-1350.
  43. Fullerton G. M., Allan A., Hilditch T., Murrag N. R. Quntitative 99mTc-DISJDA scanning and endoscopic biliary manometry in sphincter Oddi disfunction / Gut, 1988; 29: 1397-1401.
  44. Лоранская И. Д., Вишневский В. В. Изучение моторной функции желчевыделительной системы и гастродуоденальной зоны при патологии билиарного тракта / Русск. мед. журн., 2005; 7 (1): 1-7.
  45. Болдин Б. В., Каралкин А. В., Фомин Д. К. Функциональные методы исследования гепатобилиарной системы у больных желчнокаменной болезнью / Российск. гастроэнтерол. журн., 2000; 2: 21-30.
  46. Портной Л. М., Денисова Л. Б., Уткина Е. В. и др. Магнитнорезонансная холангиопанкреатография: ее место в диагностике болезней гепатопанкреатодуоденальной области / Российск. журн. гастроэнтерол., гепатол. и колопроктол., 2001; 5: 41-50.
  47. Macary M. A., Duncan M. D., Harmon J. W. et al. The role of magnetic resonance cholangiography in the management of patients with gallstone pancreatitis / Ann. Surg., 2005; 241: 119-124.
  48. Ратников В. А. Диагностические возможности и методика магнитно-резонансной томографии печени, билиарного тракта, поджелудочной железы и селезенки / Российск. журн. гастроэнтерол., гепатол. и колопроктол., 2001; 6: 28-32.
  49. Vatanabe Y., Dohke M., Ishimori T. et al. Diagnostic pitfalls of MR-cholangiopancreatography in the evaluation of the biliary tract and gallbladder / Tidsskr. Nor Laegeform / 1998; 119 (22): 3252-3256.
  50. Рафес Ю. И., Шелекетина И. И. Билиарная недостаточноcть / Врач. дело, 1972; 4: 76-78.
  51. Barthtet M., Bouvier M., Pacout C. et al. Effects of trimebutine on sphincter Oddi motility in patients with postcholecystectomy pain / Aliment. Pharmacol. Ther., 1998; 12 (7): 647-652.
  52. Плотникова Е. Ю., Рубан А. П., Багмет А. Д. Желчнокаменная болезнь, холецистэктомия - что дальше? / Вестн. клуба панкреатол., 2017; 1: 55-60 (Украина).
  53. Fosmark C. E. Management of chronic pancreatitis / Gastroenterology, 2013; 144 (6): 1282-1291.
  54. Циммерман Я. С. Cовременные возможности фармакотерапии хронического панкреатита / Клин. фармакол. и тер., 2016; 3: 59-63.

Full text is published :
Zimmerman J.S. POSTCHOLECYSTECTOMICAL SYNDROME, ITS NATURE, CLINICAL MANIFESTATIONS, DIAGNOSIS AND TREATMENT. Experimental and Clinical Gastroenterology Journal. 2017;144(08):4-11
Read & Download full text

1. Saratov State Medical University n. a. V. I. Razumovsky (Saratov, Russian Federation)

Keywords:comorbid diseases,postgastrectomy disturbances,periodontal disease

Abstract:Purpose. Definition of features of a periodontal tissues at patients with postgastrectomy disturbances and predictors of progression periodontal diseases Material and methods. The examination of 42 patients with a disease of the operated stomach and chronic generalized periodontitis at the age of 29-58 years is conducted. Endoscopic, radiological, morphological examination is conducted. Material processed statistically. Results. Clinical features of a periodontal disease against the background of the postgastrectomy disturbances are the expressed inflammatory reaction in periodontal tissues, deep periodontal pockets, suppuration from them, appreciable mobility of teeth, plentiful tooth deposits, erosions of an enamel. Predictors of emergence and advance of a periodontal disease after a resection of a stomach are disturbance of evacuation from a stomach stump, the expression of an enterogastro-ezofageal reflux, general dystrophic changes in an organism caused by malabsorption. Conclusion. Achievement of permanent remission in treatment of patients with comorbid pathology requires joint approach of gastroenterologists and stomatologists.

• References total 9 ⇓ :: .
  1. Ивашкин В. Т., Комаров Ф. И., Раппопорт С. И. Краткое руководство по гастроэнтерологии. М.: Медицинское информационное агентство. 2001: 457.
  2. Самсонов М. А., Лоранская Т. И., Нестерова А. П. Постгастрорезекционные синдромы. М.: Медицина. 1984: 192.
  3. Осадчук М. А., Островская Л. Ю., Исламова Е. А. Особенности лечения пациентов с язвенной болезнью желудка и двенадцатиперстной кишки, сочетанной с воспалительными заболеваниями пародонта. Вестник Волгоградского государственного медицинского университета 2009; 1: 76-80.
  4. Горбачева И. А., Орехова Л. Ю., Сычева Ю. А. и соавт. Воспалительные заболевания пародонта в полиморбидном континууме, интегративный подход к лечению. СПб.: ООО «АСпринт». 2012: 140.
  5. Калинина А. В., Логинова А. Ф., Хазанова А. И. Гастроэнтерология и гепатология: диагностика и лечение: руководство для врачей. М.: МЕДпресс-информ. 2013: 848.
  6. Маев И. В. Внепищеводные проявления гастроэзофагеальной рефлюксной болезни. Рос. журн. гастроэнтерол., гепатол., колопрок-тол. 2005; 5: 56-67.
  7. Горбачева И. А., Орехова Л. Ю., Сычева Ю. А. Пути преодоления полипрагмазии при лечении современных полиморбидных больных с воспалительными заболеваниями пародонта. Пародонтология 2015; 2(75): 15-18.
  8. Булкина Н. В., Ведяева А. П., Савина Е. А. Коморбидность заболеваний пародонта и соматической патологии. Медицинский вестник Северного Кавказа 2012; 3: 110-115.
  9. Цепов Л. М. Заболевания пародонта: взгляд на проблему. М.: МЕДпресс-информ. 2006: 192.

Full text is published :
Ostrovskaya L.U., Bulkina N.V. CONDITION OF PERIODONTAL TISSUES AT PATIENTS WITH POSTGASTRECTOMY SYNDROM. Experimental and Clinical Gastroenterology Journal. 2017;144(08):12-16
Read & Download full text

1. Medical Academy named after S. I. Georgievsky, Crimean Federal University named after V. I. Vernadsky (Simferopol, Russian Federation)

Abstract:Objective: individualization of therapy in patients with pulmonary tuberculosis and in HIV-coinfected patients who are undergoing antituberculosis and antiretroviral therapy, by studying the risk factors of drug-induced liver disease (polymorphism of NAT2 and cytochrome P450 2E 1). Materials and methods. 200 patients were examined during the study. 120 patients with newly diagnosed pulmonary tuberculosis (TB) who were undergoing anti-tuberculosis therapy according to I or III regimens have been identified among them. Patients with or without drug-induced liver disease on the background of anti-tuberculosis chemotherapy were studied by genotyping of cytochrome P450 2E 1 and NAT2 enzymes by «real time» polymerase chain reaction (PCR) and 13C-metacetin breath test. Results. In the 2 nd group and in the 4 th group (in groups of patients with drug-induced liver disease on the background of antituberculous therapy), slow acetylators and genotype of cytochrome P450 2E 1 c1 / c1 prevailed. Conclusions. It is advisable to recommend patients in the high-risk group for the development of drug-induced liver disease to determine the activity of cytochrome P450 2E 1 and NAT2 enzymes by genotyping and phenotyping in order to select the optimal scheme of anti-tuberculosis therapy, which will lead to increased adherence of patients to therapy and improvement of patients’ quality of life.

• References total 32 ⇓ :: .
  1. Plan to Stop TB in 18 High-priority Countries in the WHO European Region, 2007-2015. World Health Organization.
  2. Global tuberculosis report 2013. Geneva, Switzerland: WHO; 2013. World Health Organization. WHO/HTM/TB/2013.11.http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf. Accessed September 2014.
  3. «Государственная программа Российской федерации: развитие здравоохранения». Распоряжение правительства Российской Федерации от 24 декабря 2012 г. № 2511- р.
  4. Уточненный отчет о ходе реализации и оценке эффективности государственной программы Российской Федерации «Развитие здравоохранения» за 2014 год. https://www.rosminzdrav.ru/ministry/programms/health/info
  5. Государственная программа Российской Федерации «Развитие здравоохранения» Постановление правительства Российской Федерации. От 15 апреля 2014 года N 294
  6. Перельман М. И. Фтизиатрия. Национальное руководство. - 2011 год
  7. Баласанянц Г. С. Гепатотоксические реакции и гепатопротективная терапия во фтизиатрии. «Туберкулез и болезни легких», 2015, № 8, с. 48-52. ФГБУ «СПбНИИФ» М3 РФ, г. Санкт-Петербург
  8. GUIDELINE Consensus statement: Management of drug-induced liver injury in HIV-positive patients treated for TB Southern African Journal of HIV Medicine, Vol. 14, No 3 (2013)
  9. Иванов А. К., Шевырева Е. В., Сакра А. и др. Гепатопротективная терапия больных туберкулезом в сочетании с вирусными гепатитами и ВИЧ-инфекцией // Ж. инфектологии, прилож. - 2014. - Т. 6, № 2. - С. 43.
  10. Иванова Д. А. Нежелательные побочные реакции при лечении больных туберкулезом // Туберкулез и болезни легких 2011. № 6. 60-9.
  11. Wang J.Y., Liu C. H., Hu F. C. Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect. 2011;62:448-455. [PubMed]
  12. Ungo J.R., Jones D., Ashkin D. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157:1871-1876. [PubMed]
  13. Dworkin M. S., Adams M. R., Cohn D. L. Factors that complicate the treatment of tuberculosis in HIV-infected patients. J Acquir Immune Defic Syndr. 2005;39:464-470. [PubMed]
  14. Klyarytskaya, I.L., Stilidi, E.I., Maksymova, E. V. Comparison Of Different Treatment Regimens In Patients With Nonalcoholic Fatty Liver Disease // Experimental & clinical gastroenterology. - 2015. - № 17. - P. 12-17
  15. Singla R., Sharma S. K., Mohan A. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res. 2010;132:81-86. [PubMed]
  16. White M. C., Tulsky J. P., Lee J. R. Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence. J Correct Health Care. 2012;18:131-142. [PubMed]
  17. Bose P. D., Sarma M. P., Medhi S. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E 1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol. 2011;26:312-318. [PubMed]
  18. Wang P. Y., Xie S. Y., Hao Q. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis. 2012;16:589-595. [PubMed]
  19. Singla N, Gupta D, Birbian N, Singh J. Association of NAT2, GST and CYP2E 1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity. Tuberculosis 2014, 94: 293-298. doi: 10.1016/j.tube.2014.02.003. pmid:24637014
  20. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, et al. Cytochrome P450 2E 1 Genotype and the Susceptibility to Antituberculosis Drug - Induced Hepatitis. Hepatology 2003, 37: 924-930. pmid:12668988
  21. Мамотенко Л. Д., главный внештатный фтизиатр Министерства здравоохранения Республики Крым, 2016. http://crimea.ria.ru/society/20160321/1103890624.html
  22. Mitchell J. R., Zimmerman H. J., Ishak K. G. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med. 1976;84:181-192. [PubMed]
  23. Jussi J. Saukkonen, David L. Cohn, Robert M. Jasmer et all. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. Am J Respir Crit Care Med Vol. 174. pp 935-952, 2006
  24. Getnet Yimer, Marcus Gry. Evaluation of Patterns of Liver Toxicity in Patients on Antiretroviral and Anti-Tuberculosis Drugs: A Prospective Four Arm Observational Study in Ethiopian Patients.Published: April 8, 2014. http://dx.doi.org/10.1371/journal.pone.0094271
  25. Кляритская И. Л., Максимова Е. В., Шелихова Е. О., Григоренко Е. И. Диагностика и тактика ведения пациентов с лекарственными поражениями печени: клинические рекомендации Американского колледжа гастроэнтерологов // Крымский терапевтический журнал. -2016. - № 1. - С. 5-11
  26. Lock, J. F. et al. Initial liver graft function is a reliable predictor of tacrolimus trough levels during the first post-transplant week. Clin Transplant 25, 436-443 (2011).
  27. Stockmann, M. et al. How to define initial poor graft function after liver transplantation? - a new functional definition by the LiMAx test. Transpl. Int. 23, 1023-1032 (2010)
  28. Максимова Е. В., Шелихова Е. О., Стилиди Е. И., Кляритская И. Л. Место 13С-метацетинового дыхательного теста в диагностике лекарственных поражений печени // Научный руководитель 2016. - № 5. - С. 58-64
  29. Кляритская И. Л., Максимова Е. В., Шелихова Е.О, Стилиди Е. И. 13С-метацетиновый дыхательный тест в гастроэнтерологической практике // Врач. - 2016. - № 7. - C.77-78
  30. Dr. A. Toure, M. Cabral, A. Niang et all. Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients. Toxicology Reports 3 (2016) 826-831
  31. Vidyasagar Ramappa and Guruprasad P. Aithal. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. J Clin Exp Hepatol. 2013 Mar; 3(1): 37-49.
  32. Huang Y. S., Chern H. D., Su W. J. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002; 35: 883-889. [PubMed]

Full text is published :
Kliaritskaia I.L., Shelikhova E.O., Maksimova E.V., Stilidi E.I. DAMAGE WHEN TAKING INFECTIONS - HUMAN IMMUNODEFI CIENCY VIRUS AND TUBERCULOSIS. Experimental and Clinical Gastroenterology Journal. 2017;144(08):17-22
Read & Download full text

1. Scientific clinical center JSC “Russian Railways” (Moscow, Russian Federation)
2. Russian University of friendship of people (RUDN) (Moscow, Russian Federation)

Abstract:On the basis of the endoscopic Department NUZ NCC, Russian Railways conducted a routine colonoscopy which were selected 81 patient for polypectomy. Used video system EPX-4400 Fujifilm, video endoscopes EC-590ZW/L, and EC-530WL. This system has the capability of digital and optical zoom, virtual chromoscopy FICE (spectral color separation). Used two user mode, which we consider to be optimal for routine chromoscopy tumors, FICE-0 (light spectrum 530 of the R, G, 485, 505 B; light amplification R 3, G 4, B 3) and FICE-1 (light spectrum 550 R, G, 500, B 470; light amplification R 2, G 4, B 4). Removal of tumors was performed by polypectomy and mucosal resection, using the electrosurgical unit Erbotom ICC 200, ERBE Elektromedizin company. Presents several applications of spectral color technology selection stages of diagnosis and treatment of tumors of the colon.

• References total 10 ⇓ :: .
  1. Агейкина Н. В., Дуванский В. А., Князев М. В. Альтернативный путь развития колоректального рака. Эндоскопические и морфологические особенности зубчатых поражений (обзор литературы) // Экспериментальная и клиническая гастроэнтерология. - 2013. - № 8. - С. 3-10.
  2. Агейкина Н. В., Дуванский В. А., Князев М. В. и соавт. Альтернативный путь развития колоректального рака. Гистогенетические и молекулярные особенности зубчатых поражений // Экспериментальная и клиническая гастроэнтерология. - 2014. - № 7 (107). - С. 4-12.
  3. Дуванский В. А., Белков А. В., Широкопояс А. С. Технология спектрального цветового выделения в эндоскопической диагностике колоректальных неоплазий // Росс. журнал гастроэнтерологии, гепатологии, колопроктологии, -№ 5, Т. 25. - М., 2015. - С. 114.
  4. Дуванский В. А., Белков А. В. Возможности технологии спектрального цветового выделения в диагностике колоректальных неоплазий // Лазерная медицина. - 2016. - Т. 20. - № 3. - С. 103.
  5. Князев М. В. Дуванский В. А. Эндоскопическое лечение гастроинтестинальных неоплазий - эволюция метода // Вестник хирургии им. И. И. Грекова. 2015. Т. 174. № 2. С. 130-134.
  6. Abu Dayyeh BK, Thosani N, Konda V, et al. ASGE technology committee systematic review and metaanalysis assessing the ASGE PIVI thresholds for adopting real-time endoscopic assessment of the histology of diminutive colorectal polyps. Gastrointest Endosc. 2015;81:502.e1-502.e16.
  7. Rex DK, Ahnen DJ, Baron JA et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 2012; 107: 1315-1329.
  8. Sano Y, Tanaka S, Teixeira CR et al. Endoscopic detection and diagnosis of 0-IIc neoplastic colorectal lesions. Endoscopy 2005; 37: 261-267.
  9. Su MY, Ho YP, Chen PC et al. Magnifying endoscopywith indigo carmine contrast for differential diagnosis of neoplastic and nonneoplastic colonic polyps. Dig Dis Sci 2004; 49: 1123-1127.
  10. Zauber AG, Winawer SJ, O’Brien MJ et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. NEJM 2012; 366:687-696.

Full text is published :
Belkov A.V., Duvanskiy V.A. SPECTRAL COLOR SEPARATION TECHNOLOGY WITH ENDOSCOPIC DIAGNOSIS OF COLON TUMORS. Experimental and Clinical Gastroenterology Journal. 2017;144(08):23-25
Read & Download full text

1. Peoples’ Friendship University of Russia

Keywords:biliary stenting,duodenal stenting,double stenting,self-expanding metal stents,malignant stenosis

Abstract:Aim: analysis of the results of double stenting in patients with combined biliary and pyloroduodenal malignant obstruction. Material and methods: Double stenting with self-expandable metal stents (SEMS) was performed in 9 patients with biliopancreatoduodenal (8) or gastric tumours. Simultaneous presentation of biliary and pyloroduodenal strictures was observed in 6 patients, while in 3 initial development of biliary obstruction was followed by later onset of duodenal stenosis - 4-14 months after first endoscopic (2) or percutaneous transhepatic (1) biliary stenting. In 6 cases single-stage double stenting was performed and endoscopic pyloroduodenal stent insertion was combined with biliary stenting through endoscopic (initial SEMS insertion [4] or replacement of plastic stent [1]) or percutaneous (1) route, in 3 - stents were implanted in two stages. Results: Stenting was successfully carried out in all patients. Early complications were observed in 3 cases and included acute cholecystitis (1), cholangitis (1) and hydrothorax after percutaneous biliary stent insertion (1) with no in-hospital mortality. All patients were followed up until death without any evidence of recurrent obstruction. The median survival was 91,5 days. Conclusion: According to both literature review and authors’ experience, double stenting is an effective minimally invasive palliation of patients with combined biliary and pyloroduodenal malignant obstruction. Multidisciplinary approach is necessary for best results.

• References total 23 ⇓ :: .
  1. Van Heek N. T., De Castro S. M., van Eijck C. H., et al. The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer // Ann. Surg. 2003; 238: 894-905.
  2. Maire F., Hammel P., Ponsot P., et al. Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas // Am. J. Gastroenterol. 2006; 101 (4): 735-42.
  3. Shah A., Fehmi A., Savides T. J. Increased rates of duodenal obstruction in pancreatic cancer patients receiving modern medical management // Dis. Dis. Sci. 2014; 59: 2294-2298.
  4. Lee B. H., Chin S. Y., Kim S. A., et al. Obstructive jaundice in gastric carcinoma: cause, site, and relationship to the primary lesion // Abdom. Imaging 1995; 20 (94): 307-311.
  5. Mutignani M., Tringali A., Shah S. G., et al. Combined endoscopic stent insertion in malignant biliary and duodenal obstruction // Endoscopy 2007; 39: 440-447.
  6. Maetani I. Self-expandable metallic stent placement for palliation in gastric outlet obstruction // Ann. Palliat. Med. 2014; 3 (2): 54-64.
  7. Coons H. G. Self-expanding stainless steel biliary stents // Radiology 1989; 170: 979-983.
  8. Huibregtse K., Cheng J., Coene P. P., et al. Endoscopic placement of expandable metal stents for biliary strictures - a preliminary report on experience with 33 patients // Endoscopy 1989; 21: 280-282.
  9. Neuhaus H., Hagenmüller F., Classen M. Self-expanding biliary stents: preliminary clinical experience // Endoscopy 1989; 21: 225-228.
  10. Maetani I., Ogawa S., Hoshi H., et al. Self-expanding metal stents for palliative treatment of malignant biliary and duodenal stenoses // Endoscopy 1994; 26: 701-704.
  11. Kim K. O., Kim T. N., Lee H. C. Effectiveness of combined biliary and duodenal stenting in patients with malignant biliary and duodenal obstruction // Scand. J. Gastroenterol. 2012; 47 (8-9): 962-967.
  12. Canena J., Coimbra J., Carvalho D., et al. Endoscopic bilio-duodenal bypass: outcomes of primary and revision efficacy of combined metallic stents in malignant duodenal and biliary obstructions // Dig. Dis. Sci. 2014; 59 (11): 2779-2789.
  13. Хрусталёва М. В., Годжелло Э. А., Юсупова Х. И., Галлингер Ю. И. Коррекция дуоденального стеноза с использованием металлических саморасправляющихся стентов у пациентов с опухолями панкреатобилиарной зоны // Вестник хирургической гастроэнтерологии 2011; 3: 18-24.
  14. Kikuyama M., Itoi T., Sasada Y., et al. Large-balloon technique for one-step endoscopic biliary stenting in patients with an inaccessible major papilla owing to difficult duodenal stricture // Gastrointest. Endosc. 2009; 70 (3): 568-572.
  15. Baron T. H. Management of simultaneous biliary and duodenal obstruction: the endoscopic perspective // Gut Liver 2010; 4 (Suppl. 1): S 50-56.
  16. Маринова Л. А., Бачурин А. Н., Чевокин А. Ю. Двойное билиарное и дуоденальное протезирование при стенозирующей опухоли поджелудочной железы // Анналы хирургической гепатологии 2014; 19 (3): 127-131.
  17. Nakai Y., Hamada T., Isayama H., et al. Endoscopic management of combined malignant biliary and gastric outlet obstruction // Dig. Endosc. 2017; 29: 16-25.
  18. Hamada T., Nakai Y., Isayama H., et al. Duodenal metal stent placement is a risk factor for biliary metal stent dysfunction: an analysis using a time-dependent covariate // Surg. Endosc. 2013; 27 (4): 1243-1248.
  19. Hamada T., Isayama H., Nakai Y., et al. Antireflux metal stent as a first-line metal stent for distal malignant biliary obstruction: a pilot study // Gut and Liver 2017; 11 (1): 142-148.
  20. Khashab A. M., Valeshabad A. K., Leung W., et al. Multicenter experience with performance of ERCP in patients with an indwelling duodenal stent // Endoscopy 2014; 46: 252-255.
  21. Lee E., Gwon D. I., Ko G. Y., et al. Percutaneous biliary covered stent insertion in patients with malignant duodenobiliary obstruction // Acta Radiol. 2015; 56 (2): 166-173.
  22. Moon J. H., Choi H. J. Endoscopic double-metallic stenting for malignant biliary and duodenal obstructions // J. Hepatobiliary Pancreat. Sci. 2011; 46: 252-255.
  23. Itoi T., Itokawa F., Sofuni A., et al. Endoscopic ultrasound-guided double stenting for biliary and duodenal obstruction // J Hepatobiliary Pancreat. Sci. 2011; 18: 664-672.

Full text is published :
Davydova S.V., Fedorov A.G., Klimov A.E. STENTING COMBINED WITH BILIARY OBSTRUCTION AND TUMOR PILORODUODENALNOY. Experimental and Clinical Gastroenterology Journal. 2017;144(08):26-32
Read & Download full text

1. FGAOU VO First Moscow State Medical University. THEM. Sechenov Ministry of Health of Russia (Moscow, Russian Federation)

Keywords:genetic factors,features of a current,the diagnosis,the forecast,indications to treatment,schemes of treatment

Abstract:The review purpose - despite achievements in a comprehension of a pathogenesis and treatment of autoimmune hepatitis still remain unresolved a number of questions, explaining clinical features, change of diagnostic criteria. New researches and emergence of larger cohorts of patients frame unique opportunities to transfer achievements of science to new methods of treatment which will help to improve quality of life and the forecast of patients with AIG. Along with the antibodies of histocompatability defining predisposition to a serious current the role of the transcription factor designated as the autoimmune regulator of the 1st type is undoubted; it is possible that mutations of this transcription factor cause loss of tolerance to liver autoantigens. As the target for influence of drugs is considered by “interface hepatitis”. At diagnostic observation over 25 patients from 3 to 18 years we noted continuously recurrent course of a disease from the death or transition to cirrhosis that determined terms of dispensary observation from 4 to 14 months. The explanation of diagnostic criteria of autoimmune hepatitis is given in article. At the same time accurately follows that the scheme of treatment of AIG depends on options of disease. The combination therapy of glucocorticosteroid drugs and azatioprin considerably increased life expectancy of these serious patients. Various concrete schemes of treatment are considered and advantages of alternative therapy and transplantation.

• References total 13 ⇓ :: .
  1. Ивашкин В. Т., Буеверов А. О. Аутоиммунные заболевания печени в практике клинициста. - М.: Издательский дом М-Вести. - 2011. 112 с.
  2. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938.
  3. Boberg KM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011;54:374-385.
  4. Czaja A. J. Autoimmune hepatitis//Handbook of Liver Disease. - 1998. - P. 63-83.
  5. Seo S. et al. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol 2008;23: 1410-4.
  6. Strassburg C.P, Manns M.P. Autoimmune hepatitis in the elderly: what is the difference?. J Hepatol 2006; 45:480-482.
  7. Nouri K., Hegarty J., Eddleston A. L.W.P. Deffective suppressor T-cell control of cell proliferation in chronic liver disease//Liver. - 1982. - Vol. 2, N 3. - P. 270-274.
  8. В. Т. Ивашкин, М. В. Маевская и др. Алгоритм диагностики и лечения в гепатологии. «МЕДпресс-информ»2017
  9. Schüler A, Manns MP. Treatment of autoimmune hepatitis. In: Arroyo V, Bosch J, Rodés J, ed. Treatment in hepatology, Paris: S Masson; 1995:375-38Schüler A., Manns M. P., 1995
  10. Manns M. P. et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51:2193-221388.
  11. Hennes E. M., Oo Y. H., Schramm C. et.al. Mycophenolate mofetil as a second line therapy in autoimmune hepatitis?// Am. J Gastroenterol. - 2008; v.103-p.3063-3070
  12. Vogel A. et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 2004; 18:62-69.
  13. Manns MP, Bahr MJ. Recurrent autoimmune hepatitis after liver transplantation - when non-self becomes self. Hepatology 2000; 32:868-870

Full text is published :
Podymova S.D. SOLVED AND UNSOLVED PROBLEMS IN THE DIAGNOSIS AND TREATMENT OF AUTOIMMUNE HEPATITIS. Experimental and Clinical Gastroenterology Journal. 2017;144(08):33-44
Read & Download full text

1. Volgograd state Medical University (Volgograd, Russian Federation)

Keywords:pancreatitis,alcohol,pain syndrome,incretory insufficiency,secretory insufficiency,maldigestion,malabsorbtion,steatorrhea,amylase,enzyme preparations,proton pump inhibitors,H2-histamine blockers

Abstract:This review represents the data on classification of chronic alcoholic pancreatitis; discusses symptoms of this disease; studies diagnostic standards at inspection of patients with alcoholic pancreatitis; acquaints with principles of complex treatment of this pathology.

• References total 38 ⇓ :: .
  1. Кучерявый Ю. А. Пациент с хроническим панкреатитом: ошибки ведения, возможные причины и пути решения // Гастроэнтерология. - Приложение Consilium medicum. - 2011; 1: 46-55.
  2. Комаров Ф. И., Осадчук М. А., Осадчук А. М. Практическая гастроэнтерология. - М.: «МИА», 2010. - 480 с.
  3. Богер М. М. Панкреатиты. Новосибирск, 1984. 198 с.
  4. Охлобыстин А. В. Современные возможности терапии хронического панкреатита / А. В. Охлобыстин, Н. Баярмаа // Врач. - 2010. - № 2. - С. 10-14.
  5. Скворцов В. В. Внутренние болезни. - М.: Эксмо, 2014. - 1072 с.
  6. Скворцов В. В., Тумаренко А. В. Клиническая гастроэнтерология: краткий курс / В. В. Скворцов, А. В. Тумаренко. - Санкт-Петербург: Спецлит, 2015. - 183 с.
  7. Скворцов В. В., Тумаренко А. В. Первая врачебная помощь при обострении хронического панкреатита // Справочник врача общей практики. - 2010. - N 11. - С. 26-31.
  8. Тумаренко А. В., Скворцов В. В. Диагностика и лечение хронического панкреатита //Терапевт. - 2013. - N 8. - С. 25-36.
  9. Скворцов В. В., Тумаренко А. В. Актуальные вопросы диагностики и лечения хронического панкреатита // Медицинский алфавит. Фармакотерапия. - 2014. - N 1. - С. 24-28.
  10. Тумаренко А. В., Скворцов В. В. Место заместительной ферментной терапии в лечении хронического панкреатита в детском возрасте //Медицинский совет. - 2014. - N 14. - С. 72-76.
  11. Внутренние болезни по Т. Р. Харрисону. Под редакцией Э. Фаучи, Ю. Браунвальда. В 10 томах. Практика, Москва, 2005.
  12. Гастроэнтерология: Клинические рекомендации / Под ред.В.Т.Ивашкина. - 2-е изд., испр. и доп. - М.: ГЭОТАР-Медиа, 2009. - 208 с.
  13. Ивашкин В. Т., Маев И. В. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению хронического панкреатита// Российский журнал Гастроэнтерологии, Гепатологии, Колопроктологии. - 2014. - № 14. - С. 70-97.
  14. Ивашкин В. Т., Хазанов А. И., Пискунов Г. Г. и др. О классификации хронического панкреатита // Клин мед. - 1990. - 10:96-9.
  15. Бахтин В. А., Янченко В. А., Прокопьев В. С. К вопросу о классификации хронического панкреатита //Вятский медицинский вестник. - № 2-4. - 2009.
  16. Галова Е. А. Хронический панкреатит: тактика ведения пациентов // Медицинский совет. - № 4. - 2013.
  17. Маколкин В. И., Овчаренко В. И. Внутренние болезни. М., Медицина, 2004. С. 353-365.
  18. Кляритская И. Л., Вильцанюк И. А. Опыт применения препарата «Пангрол 20 000» у больных хроническим панкреатитом. //Крымский терапевтический журнал. - 2008. - № 1. - т. 11. - С. 65-70.
  19. Губергриц Н. Б., Лукашевич Г. М. Панкреатогенный сахарный диабет// Российский журнал Гастроэнтерологии, Гепатологии, Колопроктологии. - 2007. - № 6. - С. 11-16.
  20. Kleeff J., Friess H., Korc M., Buchler M. W. Chronic pancreatitis: pathogenesis and molecular aspects // Ann.Ital.Chir. - 2000. - Vol.71 (l). - P. 3-10.
  21. Anderson D. K. The Evolution of the Surgical Treatment of Chronic Pancreatitis / D. K. Anderson, C. F. Frey // Ann. Surg. - 2010. - Vol. 251. - P. 18-32.
  22. Banks P. A. The management of acute and chronic pancreatitis / P. A. Banks, D. L. Conwell, P. P. Toskes // Gastroenterol. Hepatol. (NY). - 2010. - Vol. 6, № 2, Suppl. 3. - P. 1-16.
  23. Detlefsen S. Fibrogenesis in alcogolic chronic pancreatitis: the role of tissue necrosis, macrophages, myofibroblasts and cytokines / S. Detlefsen, B. Spos, B. Feyerabend et al. // Mod. Pathol. - 2006. - Vol. 19, № 8. - P. 1019-1026.
  24. Pandol S. J. Investigating the pathobiology of alcoholic pancreatitis / S.J.
  25. Pandol, A. Lugea, O. A. Mareninova et al. // Alcohol Clin. Exp. Res. - 2011. - Vol. 35, № 5. - P. 830-837.
  26. Stevens T. Endoscopic ultrasound for the diagnosis of chronic pancreatitis / T. Stevens, M. A. Parsi // World J. Gastroenterol. - 2010. - Vol.16, № 23. - P. 2841-2850.
  27. Кучерявый Ю., Тибилова З., Андреев Д., Смирнов А. Значение мутации N 34S в гене SPINK1 в модификации клинического течения хронического панкреатита. Врач. 2013; 10: 28-32.
  28. Кучерявый Ю. А. Оценка эффективности комбинированной антисекреторной и полиферментной терапии при хроническом панкреатите с тяжелой внешнесекреторной недостаточностью. РЖГГК. 2004; 2: 78-83.
  29. Кучерявый Ю. А. Тактика ведения больных хроническим панкреатитом. Справочник поликлинического врача. 2012; 4: 69. 30
  30. Кучерявый Ю. А., Маев И. В. Тактика ведения больного хроническим панкреатитом через призму проекта рекомендаций РГА 2013 года. Доктор.Ру. 2014; 2: 23-32.
  31. Маев И. В., Дичева Д. Т., Андреев Д. Н. Актуальные аспекты патогенетической фармакотерапии хронического билиарнозависимого панкреатита. Эффективная фармакотерапия. Гастроэнтерология. 2012; 4: 12-16.
  32. Маев И. В., Зайцева Е. В., Дичева Д. Т., Андреев Д. Н. Ферментные препараты как основа лечения хронического панкреатита с внешнесекреторной недостаточностью: возможности применения и выбор в практике гастроэнтеролога. Consilium Medicum. Гастроэнтерология. 2013; 1: 61-64.
  33. Маев И. В., Казюлин А. Н., Баранская Е. К., Кучерявый Ю. А., Москалева А. Б. Нарушения питания как причинный фактор развития и усугубления панкреатита. Фарматека. 2011; 11: 16-23.
  34. Маев И. В., Кучерявый Ю. А. Заместительная ферментная терапия при панкреатической недостаточности. Клинические перспективы гастроэнтерологии, гепатологии. 2005; 5: 19-28.
  35. Маев И. В., Кучерявый Ю. А., Москалева А. Б. Квашиоркор взрослых при хроническом панкреатите. Клинические перспективы гастроэнтерологии, гепатологии. 2008; 4: 3-11.
  36. Маев И. В., Кучерявый Ю. А., Москалева А. Б. Хронический панкреатит: мифы и реалии. Фарматека. 2010; 12: 24-31.
  37. Маев И. В., Кучерявый Ю. А., Оганесян Т. С., Трошина И. В., Москалева А. Б., Устинова Н. Н., Куликовская Н. С. Фармакоэкономическая эффективность заместительной терапии различными препаратами панкреатина у больных хроническим панкреатитом с экзокринной панкреатической недостаточностью. Фарматека. 2010; 15: 98-104.
  38. Маев И. В., Кучерявый Ю. А., Самсонов А. А., Андреев Д. Н. Трудности и ошибки в тактике ведения больных хроническим панкреатитом. Терапевтический архив. 2013; 2: 65-72.

Full text is published :
Skvortsov V.V., Ustinova M.N., Khalilova U.A. DIAGNOSIS AND TREATMENT OF CHRONIC ALCOHOLIC PANCREATITIS . Experimental and Clinical Gastroenterology Journal. 2017;144(08):45-51
Read & Download full text

1. Multidisciplinary medical center of the Central Bank of the Russian Federation (Moscow, Russian Federation)

Keywords:esophageal-gastric junction,cardia,diaphragmatic constriction,metaplastic mucosa,Barrett’s esophagus,hiatal hernia

Abstract:Endoscopic picture of esophageal-gastric junction in normal and pathological conditions is still a matter of attention of domestic and international medical community: endoscopists, gastroenterologists, morphology, as well as abdominal and thoracic surgeons. Endoscopic semiotics and target biopsy of pathological focus are the basis for the diagnosis and definition of further tactics for the patient. The main issues addressed in the review 1.Anatomical Z-line position relative to the outlet of the cardia and diaphragma 2. Histological features of esophageal-gastric junction in normal 3. Options endoscopic picture in normal and in condition of metaplastic mucosa 4. The endoscopic picture with hiatal hernia

• References total 8 ⇓ :: .
  1. Руководство Американской гастроэнтерологической ассоциации по лечению ГЭРБ, 2008
  2. Руководство Общества американских гастроэнтерологов и эндоскопических хирургов по хирургическому лечению ГЭРБ, 2010
  3. Медикаментозное и хирургическое лечение ГЭРБ, систематический обзор 2010
  4. Руководство Британского гастроэнтерологического общества по диагностике и ведению пациентов с пищеводом Барретта, 2013
  5. Рандомизированное исследование LOTUS, 5-летнее наблюдение (Galmiche et al., 2011)
  6. Дронова О. Б. Анатомо-эндоскопические и клинико-функциональные основы гастроэзофагеальной рефлюксной болезни: Дисс. на соискание ученой степени д. м. н., 2008.
  7. Колесников Л. Л. Сфинктерный аппарат человека. СПб.: Специальная литература - 2000-184 с. - Монография.
  8. Маржатка З., Поддубный Б. К., Федоров Е. Д. Эндоскопия пищеварительного тракта Номенклатура OMED, Третье издание, 1996 г.

Full text is published :
Belova G.V., Rudenko O.S. ENDOSCOPIC ANATOMY OF ESOPHAGEAL-GASTRIC JUNCTION WAS NORMAL, WHEN CHITALNY HERNIAS AND CYLINDRICITY METAPLASIA OF ESOPHAGEAL MUCOSA. Experimental and Clinical Gastroenterology Journal. 2017;144(08):52-54
Read & Download full text

1. Federal State Budget Educational Institution of Higher Education «Samara State Medical University» of the Ministry of Health of the Russian Federation (Samara, Russian Federation)

Keywords:Refractory to inhibitors of proton pump gastroesophageal reflux disease,diagnosis,treatment

Abstract:Aim of the review. At a modern scientific level, to illuminate the problem of refractory to proton pump inhibitors (PPI) forms of gastroesophageal reflux disease (RFGERD). It is shown that PPI remain the standard and most effective therapy for gastroesophageal reflux disease (GERD). Patients in whom GERD symptoms are refractory to PPI should be further examined to exclude other diseases. It is possible to use different treatment options: medication, endoscopic or surgical. The response to IPP therapy can be complete (no symptoms), partial or absent. In patients with a full response to treatment with PPI, no other treatment is foreseen. Patients with partial response may require endoscopic or surgical intervention. Currently, new methods of conservative therapy of RFGERD are being actively developed. Special hopes for improvement of the symptoms of RFGERD are currently associated with the means that can provide visceral analgesia.

• References total 26 ⇓ :: .
  1. Старостин Б. Д. Гастроэзофагеальная рефлюксная болезнь (часть I). Эпидемиология, факторы риска. Гастроэнтерология Санкт-Петербурга. 2014; 1(2):2-14.
  2. Sifrim D. Acid, weakly acidic and non-acid gastro-oesophageal reflux. Eur J Gastroenterol Hepatol. 2004; 16:823-830.
  3. Fass R., Gasiorowska A. Refractory GERD: what is it? Curr Gastroenterol Rep. 2008; 10:252-257.
  4. Sharma N., Agrawal A., Freeman J. et al. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol. 2008; 6:521-524.
  5. Aziz Q., Fass R., Gyawali C. P. et al. Esophageal disoders. Gastroenterology. 2016; 150:1368-1379.
  6. Shapiro M., Green C., Bautista J. M. et al. Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid. Am J Gastroenterol. 2006; 101:1084-1091.
  7. Yoshida N., Kuroda M., Suzuki T. et al. Role of nociceptors/neuropeptides in the pathogenesis of visceral hypersensitivity of nonerosive reflux disease. Dig. Dis. Sci. 2012; 58:2237-2243.
  8. Fass R., Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009; 58:295-309.
  9. Todd J. A., Basu K. K., de Caestecker J. S. Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett’s oesophagus. Aliment Pharmacol Ther. 2005; 21:969-975.
  10. Farre R., Van Malenstein M. H., de Vos R. et al. Weakly acidic solutions containing pepsin and bile acids can increase significantly esophageal mucosa permeability (abstract). Gastroenterology. 2007; 132(4 Suppl 2): S 1897.
  11. Peghini P. L., Katz P. O., Bracy N. A. et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998; 93:763-767.
  12. Dammann H. G., Fuchs W., Richter G. et al. Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Aliment Pharmacol Ther. 1997; 11:359-364.
  13. Leite L., Lambrecht N., Sachs G. et al. Is omeprazole resistance due to mutations of cysteine 813 or 822 in the acid pump? (abstract). Gastroenterology. 1995;108: A147.
  14. Chiba N., De Gara C. J., Wilkinson J. M. et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997; 112:1798-1810.
  15. Давыдкин И. Л. Осадчук А. М. Бородулина Е. А. Гриценко Т. А. Инфильтративный туберкулез легких, язвенная болезнь и ВИЧ-инфекция (коморбидность и мультиморбидность заболеваний). Наука и инновации в медицине. 2016; 1:19-24.
  16. Holtmann G., Cain C., Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology. 1999; 117:11-16.
  17. Mizyed I., Fass S. S., Fass R. Review article: gastro-oesophageal reflux disease and psychological comorbidity. Aliment Pharmacol Ther. 2009; 29:351-358.
  18. Rohof W. O., Bennink R. J., de Jonge H. et al. Increased proximal reflux in a hypersensitive esophagus might explain symptoms resistant to proton pump inhibitors in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2014;12:1647-1655.
  19. Осадчук М. А., Осадчук А. М., Балашов Д. В., Кветной И. М. Рефрактерная форма гастроэзофагеальной рефлюксной болезни: клинико-эндоскопические, функциональные и морфофункциональные критерии. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2011; 2: 30-37.
  20. Гриценко Т. А., Давыдкин И. Л., Осадчук А. М., Косталанова Ю. В. Гастроэзофагеальная рефлюксная болезнь у пациентов, получающих полихимиотерапию: клинические, эндоскопические, морфологические и иммуногистохимические особенности. Экспериментальная и клиническая гастроэнтерология. 2015;2(114):17-23.
  21. Becker V. Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton-pump inhibitors. World J Gastroenterol. 2014; 20:4017-4024.
  22. Хуболов А. М., Толстокоров А. С., Коваленко Ю. В. Результаты антирефлюксной хирургической коррекции грыж пищеводного отверстия диафрагмы у лиц пожилого и старческого возраста. Аспирантский вестник Поволжья. 2016; 1(2): 167-171.
  23. Chowers Y., Atarot T., Pratha V. S. et al. The effect of once daily omeprazole and succinic acid (VECAM) vs. once daily omeprazole on 24-h intragastric pH. Neurogastroenterol Motil. 2012; 24:426-431.
  24. Vela M. F., Tutuian R., Katz P. O. et al. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther. 2003;17:243-251.
  25. Adachi K., Furuta K., Miwa H. et al. A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory non-erosive reflux disease. Dig Dis Sci. 2012; 57:1609-1617.
  26. Maradey-Romero C., Fass R. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil. 2014; 20:6-16.

Full text is published :
Osadchuk A.M., Davydkin I.L., Gricenko T.A., Kurtov I.V. et al. REFRACTORY TO PROTON PUMP INHIBITORS GASTROESOPHAGEAL REFL UX DISEASE. Experimental and Clinical Gastroenterology Journal. 2017;144(08):55-61
Read & Download full text

1. Moscow Clinical Scientific Center (Moscow, Russian Federation)
2. Medical Radiological Research Center name by A. F. Tsyb (Moscow, Russian Federation)

Keywords:mesenchymal stromal cells,reparative processes,inflammatory bowel diseases,model of colitis

Abstract:Transplantation of allogenic mesenchymal stromal cells (MSCs) is used for the stimulation of reparative processes in various organs and tissues. The aim of our work was to assess the reparative potential of MSCs to bone marrow in acute and chronic damage to the intestines of Wistar rats induced by sodium dextran-sulfate (DS). An experiment to study the reparative capacity and safety of transplantation of MSCs bone marrow in acute and chronic intestinal damage induced by sodium DS was carried out on Wistar rats. Transplantation of mesenchymal stromal cells in this experiment showed improvement of the histological picture of the intestinal mucosa. Experience has demonstrated the feasibility of this method in the field of medical use of stem cells the type that is aimed at increasing the effectiveness of therapy of chronic inflammatory bowel diseases.

• References total 12 ⇓ :: .
  1. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6: 523-644.
  2. Timothy J., Nelson, M.D., Ph.D., Atta Behfar, M.D., Ph.D., and Andre Terzic, M.D., Ph.D. Strategies for Therapeutic Repair: The “R 3” Regenerative Medicine Paradigm. Clin Transl Sci. 2008 September 10; 1(2): 168-171.
  3. Князев О. В., Парфенов А. И., Щербаков П. Л., Хомерики С. Г., Ручкина И. Н., Конопляников А. Г. Эффективность и безопасность мезенхимальных стромальных клеток костного мозга у больных с рефрактерными формами болезни Крона. Клеточная трансплантология и тканевая инженерия. Том VIII, № 1, 2013, стр. 76-84.
  4. Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut. 2011;60:788-798.
  5. Doorn J, Moll G, Le Blanc K, et al. Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements. Tissue Eng Part B Rev. 201218:101-115.
  6. Duijvestein M, Vos AC, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study.Gut. 2010;59:1662-1669.
  7. Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol Mech Dis. 2011;6:457-478.
  8. DelaRosa O, Lombardo E, Beraza A, et al. Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng Part A. 2009;15:2795-2806.
  9. Maccario R, Podest`a M, Moretta A, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD 4 + T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 2005;90:516-525.
  10. Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004;103:4619-4621.
  11. Griffin MD, Ryan AE, Alagesan S, et al. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? Immunol Cell Biol. 2013; 91:40-51.
  12. Ceron W, Lozada-Requena I, Ventocilla K, Jara S, Pinto M, Cabello M, Aguilar JL. Mesenchymal stem cells: definitions, culture and potential applications. Rev Peru Med Exp Salud Publica. 2016 Oct-Dec;33(4):758-771. doi: 10.17843/rpmesp.2016.334.2563.

Full text is published :
Knyazev O.V., Khomeriki S.G., Trubitsyna I.E., Konoplyannikov A.G. TRANSPLANTATION OF MESENCHYMAL STROMAL CELLS OF BONE MARROW ON THE MODEL OF ULCERATIVE COLITIS. Experimental and Clinical Gastroenterology Journal. 2017;144(08):62-66
Read & Download full text

1. Pirogov Russian National Research Medical University (Moscow, Russian Federation)
2. Krasnoyarsk State Medical University named after Prof. V. F. Voino-Yasenetsky (Moscow, Russian Federation)
3. Federal State Autonomous Institution “National Scientific and Practical Center of Children’s Health” Of the Ministry of Health of the Russian Federation (Moscow, Russian Federation)

Abstract:Objective: to develop an algorithm for step-by-step differential diagnosis of congenital cholestatic diseases in children based on a multifactorial statistical analysis of the characteristics of the course of diseases for their early detection and determination of the tactics of medical care. Patients and research methods. 81 children aged 1 month to 16 years (average age 5 years 2 months ± ± 6 months), of which 20 children with biliary atresia (BA), 17 children with hereditary tyrosinemia type 1 (HT1), 23 children with progressive familial intrahepatic cholestasis (PFIHC), 21 children with Alagilla syndrome (SA). Were performed retrospective analysis of the history and clinical manifestations of disease in the debute; biochemical blood examination; hepatobiliscintiraphy (HBSH). Results. It was found that the most significant clinical symptoms at the onset of congenital cholestatic disease in infants is prolonged jaundice in the neonatal period, hypocolia or Acholia of the stool, hepatomegaly or hepatosplenomegaly in children born with intrauterine hypotrophy from pregnancy, which was threatened with interruption. Dyspepsia syndrome, fever, and rickets in disease onset is characteristic of hereditary tyrosinemia type 1. It has been proven that using HBSH differentiates the type of intrahepatic cholestasis - intracellular sinusoidal from ductular, as well as differentiation of PFIHC and BA from SA and NT1, for example, metabolic diseases involving liver pathology are considered. It is shown that the most significant laboratory parameters in the differential diagnosis of cholestatic diseases in young children are the levels of gammaglutamyltranspeptidase (GGT), total bilirubin with a predominance of direct fraction and alanine aminotransferase (ALT). A set of indicators of changes in GGT, ALT, and bilirubin allows to differentiate congenital cholestatic disease. An algorithm for step-by-step differential diagnosis of congenital cholestatic diseases in young children has been developed. Conclusions. A timely, step-by-step differential diagnosis of congenital cholestatic diseases in children allow early detection of these diseases and determine the correct patient management tactics, including screening for the necessary surgical treatment. Early differential diagnosis of cholestasis in infants will allow to prevent disability in children, as well as to influence such a significant indicator as infant and child mortality.

• References total 25 ⇓ :: .
  1. Russo P, Magee JC, Boitnott J, Bove KE, Raghunathan T, Finegold M, Haas J, Jaffe R, Kim GE, Magid M, Melin-Aldana H, White F, Whitington PF, Sokol RJ. Design and validation of the biliary atresia research consortium histologic assessment system for cholestasis in infancy. Clin Gastroenterol Hepatol. - 2011;9:357-62e2.
  2. Azar G, Beneck D, Lane B. Atypical morphologic presentation of biliary atresia and value of serial liver biopsies. J Pediatr Gastroenterol Nutr. - 2002;34:212-5.
  3. Hwa Pyung Lee, Ben Kang, So Yoon Choi, Sanghoon Lee, Suk-Koo Lee, Yon Ho Choe. Outcome of Alagille Syndrome Patients Who Had Previously Received Kasai Operation during Infancy: A Single Center Study. Pediatr Gastroenterol Hepatol Nutr. - 2015 Sep. 18(3): 175-179.
  4. Hartley J, Harnden A, Kelly D. Biliary atresia. BMJ 2010;340: c2383.
  5. El-Guindi MA, Sira MM, Sira AM, Salem TA, El-Abd OL, Konsowa HA, El-Azab DS, Allam AA. Design and validation of a diagnostic score for biliary atresia. Journal of hepatology 2014; 61(1): 116-23.
  6. Gupta DK, Srinivas M, Bajpai M. AIIMS clinical score: a reliable aid to distinguish neonatal hepatitis from extra hepatic biliary atresia. Indian journal of pediatrics 2001; 68(7): 605-8.
  7. El-Guindi MA, El-Said HH, Hussein MH, Nassar RE, Sira AM. Urinary urobilinogen in biliary atresia: A missed, simple and cheap diagnostic test. Hepatology research: the official journal of the Japan Society of Hepatology 2015.
  8. Tiao MM, Tsai SS, Kuo HW, Chen CL, Yang CY. Epidemiological features of biliary atresia in Taiwan, a national study 1996-2003. Journal of gastroenterology and hepatology 2008; 23(1): 62-6.
  9. Mieli-Vergani G, Vergani D. Biliary atresia. Semin Immunopathol 2009; 31(3): 371-81.
  10. Yang JG, Ma DQ, Peng Y, Song L, Li CL. Comparison of different diagnostic methods for differentiating biliary atresia from idiopathic neonatal hepatitis. Clin Imaging 2009;33:439-46.
  11. Anshu Srivastava. Progressive Familial Intrahepatic Cholestasis. J Clin Exp Hepatol. 2014;4(1):25-36.
  12. Frongillo F, Bianco G, Silvestrini N. Acute Liver Failure in an Adult, a Rare Complication of Alagille Syndrome: Case Report and Brief Review. Transplant Proc. 2015 Sep;47(7):2179-81.
  13. Дж. Г. Солвей. Наглядная медицинская биохимия / ГЭОТАР-Медиа. - 2011. - 136с
  14. Kaye AJ, Rand EB, Munoz PS, Spinner NB, Flake AW, Kamath BM. Effect of Kasai procedure on hepatic outcome in Alagille syndrome. J Pediatr Gastroenterol Nutr. 2010;51:319-321
  15. Holme E., Lindstedt S. Diagnosis and management of tyrosinemia type I. Curr Opin Pediatr. 1995; 7:726-32
  16. Полякова С. И., Савостьянов К. В., Пушков А. А. Наследственная тирозинемия 1-го типа - что нужно знать педиатрам. Практика педиатра. 2014 февраль, с. 4-16
  17. Sokol RJ, Mack C, Narkewicz MR, Karrer FM. Pathogenesis and outcome of biliary atresia: current concepts. J Pediatr Gastroenterol Nutr. 2003;37:4-21
  18. Davenport M, Grieve A. Maximizing Kasai portoenterostomy in the treatment of biliary atresia: medical and surgical options. S Afr Med J. 2012;102:865-867
  19. Cheremisinova I. S., Shakhov B. Е. Actual Radiodiagnosis Technologies of Hepatic Cancer. Sovremennye tehnologii v medicine. 2012; (4): 115-120
  20. Логинов А. С., Решетняк В. И. Механизм развития внутрипеченочного холестаза и лечение больных первичным билиарным циррозом печени: научное издание; 4 Рос. нац. конгр. «Человек и лекарство», Москва, 8-12 апр., 1997. - М., 1997. - С. 75.
  21. Sun S, Chen G, Zheng S, Xiao X, Xu M, Yu H, Dong R. Analysis of clinical parameters that contribute to the misdiagnosis of biliary atresia. J Pediatr Surg. 2013;48:1490-1494
  22. Tang KS, Huang LT, Huang YH, Lai CY, Wu CH, Wang SM, Hwang KP, Huang FC, Tiao MM. Gamma-glutamyl transferase in the diagnosis of biliary atresia. Acta Paediatr Taiwan. 2007;48:196-20
  23. Liu C, Aronow BJ, Jegga AG, Wang N, Miethke A, Mourya R, Bezerra JA. Novel resequencing chip customized to diagnose mutations in patients with inherited syndromes of intrahepatic cholestasis. Gastroenterology. 2007;132(1):119-26.
  24. Pawlikowska L., Strautnieks S., Jankowska I. Differences in presentation and progression between severe FIC 1 and BSEP deficiencies. J Hepatol. 2010;53:170-178
  25. Martinez AM, Cedilos CAM, Zermeno JN. Dermatologic manifestations of Alagille syndrome. Bol Med Hosp Infant Mex. 2012;69(2):132-36.

Full text is published :
Volynets G.V., Khavkin A.I., Panfilova V.N., Nikitin A.V. DIFF ERENTIAL DIAGNOSIS OF CONGENITAL CHOLESTATIC DISEASES IN CHILDREN. Experimental and Clinical Gastroenterology Journal. 2017;144(08):67-74
Read & Download full text

1. Izhevsk state medical Academy, Ministry of health of Russia (Izhevsk, Russian Federation)

Keywords:cholelithiasis,hormones,mineral water “Uvinskaya”

Abstract:The pathogenesis of diseases of the digestive system, assigned role to the disturbances of hormonal homeostasis now. In non-drug treatment of these diseases, drinking mineral waters take a special place. Relatively new are the studies on the effect of mineral waters (MV) on the level of hormones. The aim of the research. Stadying of hormonal status in the process of non-drug therapy in patients with pre-stagnant stage of cholelithiasis (SCI). Material and methods. 96 patients suffering from the pre-stone stage of LCB were examinated. Perform research clinical observations of gallbladder function during a single dose of MV “Uvinskaya” (Udmurt Republic). During the course of treatment, the level of hormones (cortisol, insulin, C-peptide) in the blood was studied by the method of immunoenzymatic analysis. The results of the study revealed that after a single dose of MV, the gallbladder volume was reliably reduced in patients with pre-stagnant stage of GAD. It is noted that the balance between catabolism (in the form of cortisol reduction) and anabolism (in the form of an increase in the level of insulin and C-peptide) is reached by the end of the course of therapy. Conclusion: Taking MV Uvinskaya at the pre-stone stage of LCB actively affects hormonal homeotas, improving the function of not only the gallbladder and pancreas, but also reducing the stress effect in the form of the formation of a new level of functioning of the digestive system, close to the physiological.

• References total 12 ⇓ :: .
  1. Иванченкова Р. А. Хронические заболевания желчевыводящих путей / Р. А. Иванченкова. - Москва: Издательство «Атмосфера», 2006. - 416 с.
  2. Иванченкова Р. А. Хронические заболевания желчевыводящих путей / Р. А. Иванченкова. - Москва: Издательство «Атмосфера», 2006. - 416 с.
  3. Желчнокаменная болезнь как возможное проявление системной патологии органов пищеварения (монография) / Я. М. Вахрушев, А. Ю. Горбунов, Е. В. Сучкова // Ижевск, 2015. - 148 с.
  4. Циммерман Я. С. Природные (естественные) лечебные факторы, применяемые в гастроэнтерологии (курортная терапия) / Я. С. Циммерман // Современные аспекты восстановительной медицины, курортологии и физиотерапии: материалы межрегион. науч.-практ. конф., посвящ. 50-летию санаторию «Металлург» и 450-летию добровольного вхождения Удмуртской Республики в состав Рос. гос-ва. - Ижевск, 2008. - С. 77-89.
  5. Тудакова В. Г. Эффективность сульфатной магниево-кальциевой минеральной воды в лечении больных хроническим холециститом / В. Г. Тудакова, Е. В. Владимирский, Т. Г. Кунстман // Вопросы курортологии, физиотерапии и лечебной физической культуры. - 2013. - № 3. - С. 41-44.
  6. Benefical effect of sulphate-bicarbonate-calcium water on gallstone risk and weight control // S. G. Corradini [et al.] / World J. Gastroenterol. - 2012. - Vol. 18 (9). - P. 930-937.
  7. Фролков В. К. Влияние питьевых минеральных вод на метаболический синдром (клинико-экспериментальное исследование) / В. К. Фролков, Д. А. Еделев // Вопросы курортологии, физиотерапии и лечебной физической культуры. - 2006. - № 3. - С. 26-28.
  8. Ефименко Н. В. К вопросу о современных аспектах механизмов действия питьевых минеральных вод // Материалы юбилейной научно-практической конференции, посвященной 150-летию Русского Бальнеологического Общества. - Пятигорск. - 17-18 октября 2013. - С. 291-293.
  9. Филимонов Р. М. Минеральная вода как важный фактор нутритивной поддержки гомеостаза организма // Экспериментальная и клиническая гастроэнтерология. - 2015. - № 8. - С. 21-24.
  10. Лазебник Л. Б. Насколько реальна и эффективна первичная профилактика холецистолитиаза? / Л. Б. Лазебник, А. А. Ильченко // Экспериментальная и клиническая гастроэнтерология. - 2011. - № 4. - С. 3-6.
  11. Шаляпина В. Г. Реактивность гипофизарно-адренокортикальной системы на стресс у крыс с активной и пассивной стратегиями поведения / В. Г. Шаляпина, В. В. Ракицкая // Российский физиологический журнал. - 2003. - Т. 89, № 5. - С. 585-590.
  12. Полушина, Н. Д. Экспериментально-клинические параллели гормономодулирующего действия питьевых минеральных вод / Н. Д. Полушина, В. К. Фролков // Вопросы курортологии, физиотерапии и лечебной физической культуры. - 1996. - № 6. - С. 28-31.

Full text is published :
Gorbunov A.Yu., Tronina D.V. CHANGE IN THE HORMONAL STATUS IN CHOLELITHIASIS IN THE PROCESS OF TREATMENT WITH MINERAL WATER "UVINSKAYA". Experimental and Clinical Gastroenterology Journal. 2017;144(08):75-78
Read & Download full text

1. Herzen Moscow Cancer Research Institute, branch of National Medical Research Radiology Center (Moscow, Russian Federation)

Abstract:Introduction. Melanoma as a specific kind if dermal malignant neoplasms had been first described by Laennec as far back as 1806. On statistical evidence, frequency of a primary skin melanoma in Russia is 1.2-1.9 % among all malignant tumors. In 1820 H. Norris was the first, who discovered “a fungiform stomach disease” in a patient with skin melanoma. According to data of recent papers, metastatic lesions in the gastrointestinal tract in patients with skin melanoma are detected more than in 60 % cases at autopsy, but never diagnosed at treatment stage. Metastatic stomach lesions in patients with skin melanoma are usually asymptomatic, or symptoms are of non-specific. Classification of these lesions at first proposed by Ji Yong Ahn in 2014, and it described three macroscopic forms of melanoma metastases in gastrointestinal tract: nodular, exophytic and flat pigmented. Most of them are usually pigmented, amelanotic metastases are very rare. Objectives. The primary objective of this clinical case descripton is to show the possibilites of multimodal endoscopy, including confocal laser endomicroscopy, in metastatic stomach lesions diagnostics. Methods. Patient K., male, 69 years old, had admitted to the P. A. Herzen Moscow Cancer Research Institute, due to a district oncologist’s referral with a diagnosis “Malignant tumor of hepatopancreatobiliary region with metastases in lungs and dextrocerebral hemisphere. Chronic gastric erosions». Patient had been comprehensively examined in our institution: MRI has confirmed presence of metastatic tumor in dextral temporal region; CT described solitary metastases in the left lung inferior lobe and pancreas cervix. Multimodal upper GI endoscopic examination had been performed, including white-light high-resolution endoscopy (WLI-HD), narrow-band imaging (NBI) with optical magnification 80x (NBI-ME), endoscopic ultrasonography (EUS) and confocal laser endomicroscopy (CLE), using Cellvizio system. Results. At upper GI endoscopic examination, four nodular, eroded on top, lesions sized from 0,5 to 2 cm had been detected in the in the subcardia and in upper, middle and lower thirds of the gastric corpus. Taking in mind, that lesions are multicentric, it was necessary to differentiate primary gastric B-cell lymphoma and metastatic stomach lesions. With NBI examination, it had been discovered, that pit pattern in lesions is regular and there were no signs of surrounding mucosa pathology. Also, no significant changes of intrapapillary capillary loops shape had been detected with NBI-ME. With EUS, it had been revealed, that lesions are hypoechoic, originating from deep part of mucosa, not invading submucosa. We have performed CLE and it had been detected, that in eroded lesions there was absence of glandular or pit structures and presence of chaotically (densely in some areas) located dark irregularly shaped, considerably enlarged, tumor cells nuclei. According to these findings, we have concluded, that lesions are poor-differentiated solid tumors, probably - multiple amelanotic metastatic melanoma. Precise biopsy was performed. Due to presence of considerable neurological disorders a microsurgical resection of the dextral temporal lobe tumor was performed, not waiting for routine pathology or immunohistochemical examination. One week later, pathologists confirmed amelanotic epithelial cell melanoma metastases in gastric mucosa and resected brain tumor mass. Conclusion. Thus, metastases to the stomach mucosa are not so rare events in patients with late stages of neoplastic process at skin melanoma. Multimodal endoscopic examination with CLE provides valuable diagnostic data of stomach tumor morphology, not only carcinoma, but a solid tumors too.

• References total 40 ⇓ :: .
  1. Каприн А. Д., Старинский В. В., Петрова Е. В. (ред.) Злокачественные новообразования в России в 2012 году // М.: ФГБУ «МНИОИ им. П. А. Герцена» Минздрава России. 2014
  2. Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma. SurgOncolClin N Am. 2011 Jan;20(1):1-17.
  3. Мерабишвили В. М. Злокачественные новообразования кожи (С43-44) // Oncology.ru, Онкологическая служба Краснодарского края, 2011
  4. Thomas NE., Kricker A., Waxweiler Wt. et al. Comparison of Clinicopathologic Features and Survival of HistopathologicallyAmelanotic and Pigmented Melanomas: A Population-Based Study // JAMA Dermatol. 2014 Aug 27. doi: 10.1001/jamadermatol.2014.1348
  5. Ihde JK, Coit DG. Melanoma metastatic to stomach, small bowel, or colon. // Am J Surg. 1991 Sep;162(3):208-11.
  6. Reintgen DS, Thompson W, Garbutt J. et al. Radiologic, endoscopic, and surgical considerations of melanoma metastatic to the gastrointestinal tract. // Surgery. 1984 Jun;95(6):635-9.
  7. Berger AC, Buell JF, Venzon D et al. Management of symptomatic malignant melanoma of the gastrointestinal tract. // Ann SurgOncol. 1999 Mar;6(2):155-60.
  8. Namikawa T, Hanazaki K. Clinicopathological features and treatment outcomes of metastatic tumors in the stomach // Surg Today. 2014 Aug;44(8):1392-9.
  9. Booth JB. Malignant melanoma of the stomach. Report of a case presenting as an acute perforation and review of the literature // Br J Surg. 1965 Apr;52:262-70.
  10. Wysocki WM, Komorowski AL, Darasz Z. Gastrointestinal metastases from malignant melanoma: report of a case // Surg Today. 2004;34(6):542-6.
  11. Agrawal S, Yao TJ, Coit DG. Surgery for melanoma metastatic to the gastrointestinal tract. // Ann SurgOncol. 1999 Jun;6(4):336-44.
  12. Otani S. Malignant melanoma. // Mt Sinai J Med. 1972 Jan-Feb;39(1):48-53.
  13. Vukmirovic F., Vukmirovic M., Vukmirovic I. Multiple Simultaneos Metastases of Malignant Melanoma in the Stomach, Small and Large Intestine // Macedonian Journal of Medical Sciences. 2013 Mar 15; 6(1):56-58.
  14. Oosting SF, Peters FT, Hospers GA et al. A patient with metastatic melanoma presenting with gastrointestinal perforation after dacarbazine infusion: a case report // J Med Case Rep. 2010 Jan 15;4:10
  15. Krausz MM, Ariel I, Behar AJ. Primary malignant melanoma of the small intestine and the APUD cell concept // J SurgOncol. 1978;10(4):283-8
  16. Tabaie HA, Citta RJ, Gallo L et al. Primary malignant melanoma of the small intestine: report of a case and discussion of the APUD cell concept. // J Am Osteopath Assoc. 1984 Jan;83(5):374-7
  17. Goral V, Ucmak F, Yildirim S et al. Malignant melanoma of the stomach presenting in a woman: a case report // J Med Case Rep. 2011 Mar 9;5:94
  18. Krishna Mohan MV, Rajappa SJ, Reddy TV et al. Malignant gastrointestinal melanoma with an unknown primary // Indian J Med PaediatrOncol. 2009 Apr;30(2):87-9.
  19. Liang KV, Sanderson SO, Nowakowski GS et al. Metastatic malignant melanoma of the gastrointestinal tract // Mayo Clin Proc. 2006 Apr;81(4):511-6.
  20. Davis GH, Zollinger RW. Metastatic melanoma of the stomach // Am J Surg. 1960 Jan;99:94-6.
  21. Bäckman H, Davidsson L. Metastases of malignant melanoma in the stomach and small intestine // Acta Med Scand. 1965 Sep;178(3):329-35.
  22. Ahn JY, Hwang HS, Park YS. Et al. Endoscopic and pathologic findings associated with clinical outcomes of melanoma in the upper gastrointestinal tract // Ann SurgOncol. 2014 Aug;21(8):2532-9
  23. Woollons A, Derrick EK, Price ML. Gastrointestinal malignant melanoma // Int J Dermatol. 1997 Feb;36(2):129-31.
  24. Barnhill RL, Gupta K. Unusual variants of malignant melanoma. // ClinDermatol. 2009 Nov-Dec;27(6):564-87.
  25. Iconomou TG., Tsoutsos D., Frangia K. et al. Malignant melanoma of the stomach presenting with an unknown primary lesion // Eur J PlastSurg (2003) 26:153-155
  26. Блохин Н. Н., Петерсон Б. Е. (Ред.). Клиническая онкология // Москва, 1979
  27. Toljamo KT, Niemelä SE, Karttunen TJ et al. Clinical significance and outcome of gastric mucosal erosions: a long-term follow-up study. // Dig Dis Sci. 2006 Mar;51(3):543-7.
  28. Пирогов С. С., Унгиадзе Г. В., Кувшинов Ю. П. и др. Первый опыт использования трехрежимного видеоэндоскопа для диагностики раннего рака желудка // Журнал «Клиническая эндоскопия» № 2 (24), 2010, стр 2-11
  29. Gheorghe K. Narrow-Band Imaging Endoscopy for Diagnosis of Malignant and Premalignant Gastrointestinal Lesions // J Gastrointest Liver Dis March 2006 Vol.15 No.1, 77-82
  30. Correa P., Piazuelo B. The gastric precancerous cascade // Journal of Digestive Diseases 2012; 13; 2-9
  31. Kaltsas G, Grozinsky-Glasberg S, Alexandraki KI et al. Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms. // ClinEndocrinol (Oxf). 2014 Aug;81(2):
  32. Kato M., Kaise M., Yonezawa J. et al. Magnifying endoscopy with narrow-band imaging achieves superior accuracy in the differential diagnosis of superficial gastric lesions identified with white-light endoscopy: a prospective study // Gastrointestinal Endoscopy, Volume 72, No. 3: 2010 pp. 523-529
  33. Zhang J., Guo S., Duan Z. Application of magnifying narrow-band imaging endoscopy for diagnosis of early gastric cancer and precancerous lesion // BMC Gastroenterology 2011, 11:135
  34. Перфильев И. Б., Делекторская В. В., Кувшинов Ю. П. и др. Современные аспекты эндоскопической семиотики нейроэндокринных опухолей желудка // Российский журнал гастроэнтерологии, гепатологии и колопроктологии № 4, 2011 с. 27-36
  35. Kim GH., Kim KB., Lim EK. et al. Analysis of Endoscopic Electronic Image of Intramucosal Gastric Carcinoma Using a Software Program for Calculating Hemoglobin Index // J Korean Med Sci 2006; 21: 1041-7
  36. Tada K., Oda I., Yokoi C. et al. Pilot Study on Clinical Effectiveness of Autofluorescence Imaging for Early Gastric Cancer Diagnosis by Less Experienced Endoscopists // Diagnostic and Therapeutic Endoscopy Volume 2011, Article ID 419136, 7 pages
  37. Janssen J. The impact of EUS in primary gastric lymphoma // Best Practice & Research Clinical Gastroenterology 23 (2009) 671-678
  38. Kim GH., Kim KB., Lee SH. et al. Digital image analysis of endoscopic ultrasonography is helpful in diagnosing gastric mesenchymal tumors // BMC Gastroenterology 2014, 14:7
  39. Kim MN., Kang SJ., Kim SG et al. Prediction of Risk of Malignancy of Gastrointestinal Stromal Tumors by Endoscopic Ultrasonography // Gut and Liver, Vol. 7, No. 6, November 2013, pp. 642-647
  40. Attanoos R, Griffiths DF. Metastatic small cell melanoma to the stomach mimicking primary gastric lymphoma // Histopathology. 1992 Aug;21(2):173-5.

Full text is published :
Pirogov S.S., Sokolov V.V., Kaprin A.D., Sokolov D.V. et al. METASTATIC LESION OF THE STOMACH WITH MELANOMA OF THE SKIN: POSSIBILITIES MULTIMODAL ENDOSCOPIC DIAGNOSIS. Experimental and Clinical Gastroenterology Journal. 2017;144(08):79-86
Read & Download full text

1. N.N. Blokhin Russian Cancer Research Center (Moscow, Russian Federation)
2. N.I. Pirogov Russian National Research Medical University (Moscow, Russian Federation)
3. Evrogen Lab LLC (Moscow, Russian Federation)

Keywords:Cholangiocarcinoma,moleculartumortesting,BRAF V600E mutation,targeted therapy,dabrafenib,trametinib

Abstract:We report a case of successful targeted treatment of a patient with metastatic cholangiocarcinoma refractory to chemotherapy and immunotherapy. After detection of BRAF V600Emutationinpatient’stumor, dabrafenib + trametinib combo was started which led to dramatic improvement in patient’s general condition and regression of most of the lesions. Effectisongoingafter6monthsoftargetedtherapy. This case demonstrates potential efficiency of a molecularly targeted approach to treatment of advanced cancers.

• References total 9 ⇓ :: .
  1. Практические рекомендации по лекарственному лечению злокачественных опухолей (RUSSCO) // Злокачественные опухоли. - 2015. - № 4, спецвыпуск. - 456 стр.
  2. Charbel H., Al Kawas F. H. Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis // Curr. GastroenterolRep. - 2011. - Vol.13. - P. 182-187.
  3. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus Gemcitabine for biliary tract cancer // N Engl J Med. - 2010. - Vol. 362: 1273-1281.
  4. Putra J., de Abreu F. B., Peterson J. D. et al. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing // Exp Mol Pathol. - 2015. - Vol.99(2). - P. 240-244.
  5. Javle M., Bekaii-SaabT., Jain A. et al. Biliary Cancer: Utility of Next-Generation Sequencing for Clinical Management // Cancer. - 2016. - Sep 13. -DOI: 10.1002/cncr.30254
  6. Hyman D., Puzanov I., Subbiah V. et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations // N Engl J Med. - 2015. - Vol.373 (8). - P. 726-736.
  7. Silkin S., Startsev S., Krasnova M. et al. Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan // J Gastrointest Cancer. -2015. - Dec 19. - DOI:10.1007/s12029-015-9792-2
  8. Loaiza-Bonilla A., Clayton E., Furth E. et al. Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine // Ecancermedicalscience. - 2014. - Vol. 8. - P. 479.
  9. Hong D. S., Morris V. K., El Osta B. et al. Phase 1B Study of Vemurafenib in Combination with Irinotecan andCetuximabin Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation // Cancer Discov. - 2016. - Oct 11. - DOI:10.1158/2159-8290.CD-16-0050.

Full text is published :
Peregudova M.V., Zaretsky A.R., Breder V.V., Romanova K.A. et al. THE EFF ECTIVENESS OF TARGETED THERAPY IN A PATIENT WITH BRAF-POSITIVE METASTATIC CHOLANGIOCARCINOMA. Experimental and Clinical Gastroenterology Journal. 2017;144(08):87-90
Read & Download full text

1. State funded medical institution “City clinical hospital № 15 named after O. M. Filatov” Department of healthcare of Moscow (Moscow, Russian Federation)
2. State funded institution of higher professional education “Moscow State Medical and Dental University of A. I. Evdokimov” (Moscow, Russian Federation)

Keywords:kidney damage,antiviral therapy,monoclonal antibodies to CD 20,rituximab (mabthera),mixed cryoglobulinemia,cryoglobulinemic vasculitis,chronic viral hepatitis C

Abstract:As a clinical case we discuss cryoglobulinemic vasculitis of high activity with predominant kidney damage associated with chronic viral hepatitis C. The result of the treatment by monoclonal antibodies to CD 20 receptors - rituximab (mabthera) - confirms the efficiency of the drug in case of severe cryoglobulinemic vasculitis persistent to the standard treatment, with underlying chronic viral hepatitis C. After the therapy the hemodynamic indexes have stabilized, the hemorrhagic rash did not recur, cryoglobulinemia, proteinuria and hematuria decreased. Unfortunately the immunosuppressive therapy contributed to the increase of transaminase and cholestasis, which leaded to the need of the antiviral therapy for the elimination of the virus and relapse prevention. However, the ways of diagnostics and treatment of the patients with chronic viral hepatitis C with extrahepatic symptoms are not developed, represent serious problem and need to be further studied; the scheme of testing and antiviral therapy should be worked out.

• References total 31 ⇓ :: .
  1. Meltzer M., Franklin E. C., Elias K. et al. Cryoglobulinemia- clinical and laboratory study. II. Cryoglobulins with rheumatorid factor activity. Am I Md. 1966. 40. 837
  2. Милованова С. Ю., Игнатова Т. М., Козловская Л. В. Особенности течения хронического гепатита С с криоглобулинемией // Клиническая гепатология. - 2006.-2(1).-С. 15-18.
  3. Козловская Л. В., Гордовская Н. Б., Малышко Е. Ю., Тегай С. В., Коротчаева Ю. В. Варшавский В. А., Мирошниченко Н. Г., Милованова С. Ю. и др. Криоглобулинемическое поражение почек: особенности течения и лечение // Нефрология и диализ. - Т4. - № 1.-2002. - С. 4-8.
  4. Мухин Н. А. Нефрология // Национальное руководство краткое издание. -Москва.-2015 г.-с 597
  5. Charles E. D., Dustin L. B. Hepatitis C virus induced cryoglobulinemia. Kidney Int/ 2009; 76 (8): 818-824
  6. Ferri C. Mixed cryoglobulinemia. Orphanet J Rare. 2008: 3:25
  7. Мухин Н. А., Козловская Л. В., Малышко Е. Ю. Криоглобулинемический нефрит, ассоциированный с хронический инфекцией вируса гепатита С // Тер архив. - 2000. - 6: 1-5
  8. Agnello V., Romain P. L. Mixed cryoglobulinemia secondary to hepatitis C virus infection. Reum. Dis. Clin. of North Am. 1996; 22: (1)
  9. Giannico G., Manno C., Scbena F. P. Treatmen of glomerulonephitides associated with hepatitis C virus infection. Nephrol Dial Transplant 2000; 15: 34-38
  10. Тегай С. В., Лопаткина Т. Н., Косминкова Е. Н. и др. Поражение почек, ассоциированное с вирусами гепатита В и С. Consilium Med. 2002. Т. 4. № 7: 337-341
  11. Козловская Л, Б., Мухин Н. А., Гордовская Н. Б. и др. Факторы риска прогрессирования криоглобулинемического гломерулонефрита, связанного с вирусом гепатита С // Клиническая медицина. - 2001.-№ 4. - С.32-35.
  12. Милованова С. Ю., Игнатова М. Т., Некрасова Т. П. и др. Особенности течения хронического гепатита С с криоглобулинемией // Российский журнал гастроэнтерологии, гепатологии и проктологи, колопроктологии. - 2005. -Т. XV- № 5. - С. 48-51.
  13. Cacoud P., Poynard T., Ghillani P. et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group.Mulridepartment Virus C. Arthritis Rheum. 1999; 42:2204-2212.
  14. Ferri C. Mixed cryoglobulinemia. Orphanet J Rare. 2008: 3:25.
  15. Trejo O., Romos-Casalis M., Garcia-Carrasco M. Cryoglobulinemia: study of etiologic factors and clinical immunologic in 443 patients from a simple center. Medicine. 2001:8:252-262
  16. Дюйшеева Г. М., Гурская С. В., Каневская М. З. Криоглобулинемический васкулит тяжелого течения, ассоциированный с инфекцией вирусом гепатита С // Клиническая медицина. № 6. 2015. С. 5661. 9-11.
  17. Galossi A., Guarisco R., Bellis L., Puoti C. Extrahepatic manifestation of chronic HCV infection. J. Gastrointestin. Liver Dis. 2007; 16(1): 65-73. 20.
  18. Weidensaul D., Imam T., Holyst M. et al. Polymyositis, pulmonary fibrosis and hepatitis C. Arthr. Rheumat. 1995; 38: 437-439.29.
  19. Meliconi R., Andreoni P., Fasano L. et al. Incidence hepatitis C virus infection in Italian penitents with idiopathic pulmonary fibroris. Thorax 1996; 51:315-317.32.
  20. Matsumori F. Hepatitis C virus and cardiomyopathy. Herz 2000; 25:249254.36.
  21. Чернецова О. В., Лопаткина Т. Н., Попова И. В. и др. Синдром Шегрена при хроническом гепатите С: клинические особенности и диагностика // Тер архив. 2003; 4: 33-37.38.
  22. Галян Е. В., Кравец Е. Б., Латыпова В. Н., Дамдиндорж Д. Структурно функциональные особенности щитовидной железы у пациентов с хроническими гепатитами В и С // Бюллетень сибирской медицины. 2009; 2: 96-100. 40.
  23. Vezali E., Elefsiniotis I., Konstantinou E., Saroglou G. Thyroid dysfunction in patients with chronic hepatitis C: virus - or therapy -related? J Gastroenterol Hepatol. 2009; 24(6): 1024-9.41.
  24. Козловская Л. В., Тегай С. В., Малышко Е.Ю, Лопаткина Т. Н., Косминкова Е. Н. Поражение почек, ассоциированное с вирусами гепатитов В и С // Нефрология. Том 04/N 7/2002. -С 67-78
  25. Козловская Л. В., Тегай С. В., Малышко Е.Ю, Лопаткина Т. Н., Косминкова Е. Н. Поражение почек, ассоциированное с вирусами гепатитов В и С // Нефрология. Том 04/N 7/2002. -С 67-78
  26. Saadoun D., Rigon M. R., Sene D. et al. Rituximab plus Peg-interferon -alfa/ribavirin compared with Peginterferon-alfa/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood.2010; 116:326-334.
  27. Cacoub P., Saadoun D., Limal N. et al. PEGylated interferon alfa 2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2005;52: 911-915.
  28. Saadoun D., Reache-Rigon M., Thibault V. et al. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis. A long-term follow up study. Arthritis Rheumatism 2006;54 (11): 3696-3706.
  29. EASL Recommendation on Treatment of Hepatitis C 2015. European Association for the Study of the Liver. J. of Hepatology. 2015 Jul; 63(1): 199-236.
  30. Дунаева Н. В., Караев В. Е., Воробьева О. А., Мазинг А. В., Лапин С. В., Смирнов А. В. Противовирусная терапия хронического гепатита С, осложненного системным криоглобулинемическим васкулитом // Журнал Инфектологии. Оригинальное исследование. - Том 8.-№ 2.-2016. -С.40-47.
  31. Saadoun D., Landau D. A., Calabrese L. H., et.al. Hepatitis C - associated mixed cryoglobulinemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology. 2007; 46: 1234-1242.

Full text is published :
Sagynbaeva V.E., Golovanova E.V. CRYOGLOBULINEMIC VASCULITIS WITH KIDNEY DAMAGE ASSOCIATED WITH CHRONIC VIRAL HEPATITIS C: ANTI-CD 20 MONOCLONAL ANTIBODIES TREATMENT. Experimental and Clinical Gastroenterology Journal. 2017;144(08):91-96
Read & Download full text

1. "Polyclinic № 3" of Affairs Management of the President of the Russian Federation (Moscow, Russian Federation)

Abstract:Provides data for the treatment of constipation in 37 women in various stages of pregnancy. Highlighted that in addition to dietary measures requires taking laxatives, in particular Forlaks, has a mild laxative effect, long persistent effect and aftereffect, not causing side effects.

• References total 9 ⇓ :: .
  1. Бурков С. Г. Заболевания органов пищеварения у беременных. - М.: КРОН-ПРЕСС, 1996. - 224 с.
  2. Гребенев А. Л., Мягкова Л. П. Болезни кишечника (современные достижения в диагностике и терапии). - М.: Медицина, 1994. - 400 с.
  3. Connell A. M. Hilton C., Irvine G. Variation of bowel habit in two population samples // Br Med J, 1965; 2: 1095-1099.
  4. Lacy B. E., Mearin F., Chang L. et al. Bowel disorders // Gastroenterology 2016; 150: 1393-1407.
  5. Ивашкин В. Т., Абдулхаков Р. А., Баранская Е. К. и соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению взрослых пациентов с хроническим запором // Российский журнал гастроэнтерологии, гепатологии, колопроктологии 2014; 5: 69-75.
  6. Suares N. C., Ford A. C. Prevalance of, and risk factors for chronic idiopathic constipation in the community: systematic review and meta-analysis // Am J Gastroenterology 2011; 106: 1582-1591.
  7. Heaton K. W., Radvan Z., Cripps H. Defecatio frequency and timing, and stool form in the general population: a prospective study // Gut, 1992; 33: 818-824.
  8. Wald A. Constipation, diarrhea and symptomatic hemorrhoidis during pregnancy //Gastroent Clinics North Am 2003; 32:309-22.
  9. O’Donnell L.J.D. Bristol stool form scale // Brit Med J, 1990; 300: 439-440.

Full text is published :
Burkov S.G. CONSTIPATION IN PREGNANT WOMEN: A MODERN VIEW ON THE PROBLEM. Experimental and Clinical Gastroenterology Journal. 2017;144(08):97-100
Read & Download full text

1. Moscow state medical-dentistry University n. a. A. I. Evdokimov (Moscow, Russian Federation)
2. City Clinical Hospital No. 2 named after Dr. F. Kh. Grail (Moscow, Russian Federation)

Abstract:The article is devoted to the 95 years anniverssary of outstanding clinician-gastroenterologist, Honored Scientist of the Russian Federation Yakov Saulovich Zimmerman. Professor Ya. S. Zimmerman is the author of a unique, repeatedly republished book, that has become a reference book for many “Wise thoughts about medicine and healing: sayings, aphorisms, quotes”, as well as memories of the Great Patriotic War of 1941-1945 - “Military fate a purely civilian young man "(1995, 2010), and a collection of poems" Living Life Is Not a Field to Go "(2002). The article is published in Russian.

Full text is published :
Lazebnik L.B., Vologzhanina L.G. ANNIVERSARY YAKOV SAULOVICH TSIMMERMAN. Experimental and Clinical Gastroenterology Journal. 2017;144(08):101-102
Read & Download full text